Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab plus etoposide-cisplatin in first-line advanced small cell ovarian carcinoma of hypercalcemic type
2020-002260-31Phase 2Active
- Sponsor
- Arcagy-Gineco
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) and ovarian cancer, sponsored by Arcagy-Gineco. Primary endpoint: Complete response rate (RECIST 1.1). Started Sep 2020; status: active.
02
Drugs
03
Conditions
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)ovarian cancer
Beyond the preview
Go deeper on 2020-002260-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002260-31.